Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
IFM2005-02 trial: what clinicians have said so far
Maintenance Therapy Using Lenalidomide in Myeloma
- NCT00430365 ↗
- Completed
- University Hospital, Toulouse
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on IFM2005-02 (lenalidomide in multiple myeloma after autologous stem cell transplantation) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IFM2005-02 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 10 posts on X, typically up to 44 once built |
The trial
ClinicalTrials.gov- Official title
- Relevance of Maintenance Therapy Using Lenalidomide (Revimid®) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Myeloma
- Interventions
- lenalidomide; placebo
- Arms
- placebo group · Placebo comparator
- lenalidomide group · Experimental
- Enrollment
- 614
- Primary outcomes
- Determine the efficacy of Revlimid® at prolonging the duration of the post-transplant response.
- Sponsor
- University Hospital, Toulouse with Intergroupe Francophone du Myelome, Celgene
- Start
- Jun 2006
- Primary completion
- Sep 2017
- Results posted
- No
- Registry record
- NCT00430365 · updated Apr 6, 2026
Publications
linked from the registry- Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol. 1998 Dec;16(12):3832-42. doi: 10.1200/JCO.1998.16.12.3832. PubMed 9850028
- Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL; IFM Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10;366(19):1782-91. doi: 10.1056/NEJMoa1114138. PubMed 22571202